Pharmaceuticals News and Research

RSS

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study.

24 Sep 2013

JPM, Bill & Melinda Gates Foundation announces capital raise for first-of-its-kind investment product

A new investment fund structured by JPMorgan Chase & Co. (NYSE: JPM) and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.

24 Sep 2013

Discovery could help develop new treatments for blood diseases

Researchers in Melbourne, Australia, have found that even our immune system is subject to performance enhancement, with our bodies giving immune cells the boost they need to ensure the best team is selected to fight infections.

24 Sep 2013

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

A drug formerly used to treat the skin disorder psoriasis has shown encouraging results in a phase 2 trial to assess its effectiveness in treating type 1 diabetes, according to new research published in The Lancet Diabetes & Endocrinology.

24 Sep 2013

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.

23 Sep 2013

Karo Bio, 4D Science Team Up On Treatments For Fibrotic Diseases

...

23 Sep 2013

Advamed 2013 conference to focus on global opportunities and challenges in medical technology industry

AdvaMed 2013: The MedTech Conference begins today at the Walter E. Washington Convention Center in Washington, D.C. with a major emphasis on the opportunities and challenges facing the medical technology industry in an increasingly global marketplace.

23 Sep 2013

KaloBios Pharmaceuticals issues shares of common stock in underwritten public offering

KaloBios Pharmaceuticals, Inc. (KaloBios) today announced that it is offering to sell shares of its common stock in an underwritten public offering.

23 Sep 2013

Researchers lead two major trials to test potential treatments for asbestos-related cancer

University of Leicester researchers are leading two major trials into treatments for a type of cancer which affects those exposed to asbestos.

23 Sep 2013

Almirall and GKV-SV reach agreement on pricing of Sativex medicine in Germany

...

23 Sep 2013

Packaging Coordinators, Inc., to exhibit service offerings at CPhI 2013

Packaging Coordinators, Inc. (PCI), a global supplier of pharmaceutical commercial packaging solutions and clinical trials services is pleased to announce that it will be exhibiting its full range of services on booth 41M15 at CPhI Worldwide. Exhibiting for the first time as Packaging Coordinators, inc. since May 2013 when AndersonBrecon merged with and operated as Frazier Healthcare’s portfolio company, PCI, the company is now one of the largest suppliers of packaging supply services to the pharmaceutical industry and will be demonstrating its capabilities in clinical trials, in laboratory services and commercial services for pharmaceutical and biopharmaceutical customers.

From Packaging Coordinators Inc. (PCI) 23 Sep 2013

International symposium to focus on celiac disease and gluten-related disorders

Preliminary results from a multinational project to study the impact of early childhood nutrition on celiac disease will be among the highlights of this month's 15th International Celiac Disease Symposium, hosted by the University of Chicago Medicine Celiac Disease Center.

23 Sep 2013

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Ablynx and AbbVie today announced that they have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.

23 Sep 2013

Avon Foundation for Women launches competition to bring emerging breast cancer technologies to market

A world-wide competition to bring emerging breast cancer technologies to market is being launched by the Avon Foundation for Women, in partnership with the National Cancer Institute (NCI), part of the NIH, and the Center for Advancing Innovation.

21 Sep 2013

Study sheds light on investment levels across 12 key marketing, education and payer activities

In order for a new product to gain a foothold in today's competitive pharmaceutical market, executives must understand where and when to invest in key launch activities. At the same time, product launch leaders have to balance the goals of containing expenditures and generating a successful launch.

21 Sep 2013

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium.

21 Sep 2013

Ernest Mario School of Pharmacy, Robert Wood Johnson Medical School to launch dual-degree program

A dual-degree program combining a doctorate in pharmacy with a medical degree has been developed by Rutgers University's Robert Wood Johnson Medical School and Ernest Mario School of Pharmacy.

21 Sep 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use recommended Xofigo (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

20 Sep 2013

UdeM's IRIC and Bristol-Myers Squibb identify small molecule drug candidate against novel target

Universit- de Montr-al and the Institute for Research in Immunology and Cancer - Commercialization of Research today announced that researchers from UdeM's Institute for Research in Immunology and Cancer and Bristol-Myers Squibb Company have jointly identified a small molecule drug candidate against a novel target.

20 Sep 2013

Pharmaceuticals News and Research

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

JPM, Bill & Melinda Gates Foundation announces capital raise for first-of-its-kind investment product

Discovery could help develop new treatments for blood diseases

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Karo Bio, 4D Science Team Up On Treatments For Fibrotic Diseases

Advamed 2013 conference to focus on global opportunities and challenges in medical technology industry

KaloBios Pharmaceuticals issues shares of common stock in underwritten public offering

Researchers lead two major trials to test potential treatments for asbestos-related cancer

Almirall and GKV-SV reach agreement on pricing of Sativex medicine in Germany

Packaging Coordinators, Inc., to exhibit service offerings at CPhI 2013

International symposium to focus on celiac disease and gluten-related disorders

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Avon Foundation for Women launches competition to bring emerging breast cancer technologies to market

Study sheds light on investment levels across 12 key marketing, education and payer activities

CRF to present groundbreaking clinical trial findings at TCT 2013 scientific symposium

Ernest Mario School of Pharmacy, Robert Wood Johnson Medical School to launch dual-degree program

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

UdeM's IRIC and Bristol-Myers Squibb identify small molecule drug candidate against novel target

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence